PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the Board
Daniel Spasic, a highly experienced lifescience business leader, has been appointed as a non-executive director to the board of PathoQuest. With over 25 years of hands-on experience in the growth and development of businesses within the industry, Mr Spasic will strengthen the focus on strategic growth of PathoQuest’s provision of regulated NGS services for Biosafety Testing and Characterization of Biopharmaceuticals.
PARIS, FRANCE – November 2, 2022 – PathoQuest, the leading expert in GMP NGS services for biosafety testing, are delighted to announce that Daniel Spasic has been appointed as a non-executive director to the PathoQuest board.
Rainer Metzger,PhD, Chairman of PathoQuest’s Board of Directors welcomed Mr. Spasic by saying: “We are delighted that Daniel has accepted a position on the PathoQuest board. He brings an enormous wealth of experience in helping companies like PathoQuest to achieve their growth potential. With Daniel’s intimate knowledge of the industry as well as his impressive track record in advising on strategic growth, Daniel will help PathoQuest achieve its ambitions of growing our specialist NGS offering.”
“I’m excited to join the PathoQuest board and work close to Jean-Francois Brepson and his leadership team to further accelerate the growth of PathoQuest’s NGS service offering,” stated Spasic. “The company is operating in an important space for biologicals and its technology and proprietary sample preparation protocols are very well positioned to capture the lion share of the NGS testing market. With its newly announced US facility this growth will be further enhanced on the North American market and globally.”
Daniel Spasic holds a number of board seats across the life science industry and is a driven life science entrepreneur, strategist and growth advisor with 25 years in senior life science executive roles. He founded TFS HealthSciences (TFS) in 1996, which became a world-leading midsized global clinical Contract Research Organization (CRO). Daniel is the recipient of numerous entrepreneurial achievement awards. In 2010, Daniel received the Swedish National Award as “Man of The Year” by Ernst & Young and in the same year awarded the title “Entrepreneur of The Year” by Founders Alliance and Grant Thornton. His expertise covers biopharma- and healthcare services and technology-enabled services in clinical research. Daniel is acting as a board member for a series of Pharma Service companies in Europe and the US. Daniel is representing S-Growth Holdings LLC; a Boston based family office with investment focus in Pharma Services. He holds a technical degree in chemical engineering and an OPM from Harvard Business School. Daniel is based in Boston, Massachusetts.
PathoQuest offers biopharmaceutical companies a game-changing genomic approach at R&D, and GMP grades to ensure the biosafety of biologics like cell and gene therapy products, vaccines, and recombinant drugs. PathoQuest biosafety solutions comprise a portfolio of viral safety and genetic characterization services enabling a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences databases. PathoQuest entered into a strategic partnership with Charles River Laboratory (Boston, USA) in 2018.